Home › Funds › SymBiosis Capital Partners, LLC › RANI

SymBiosis Capital Partners, LLC position in RANI

Rani Therapeutics Holdings Inc Class A · Health Care

SymBiosis Capital Partners, LLC reported holding 3,667,585 shares of RANI (Rani Therapeutics Holdings Inc Class A) in its Q1 2026 13F filing — a position valued at US$2.7M, representing 5.11% of its reported portfolio and ranking #4 among its reported holdings. SymBiosis Capital Partners, LLC has disclosed RANI holdings in 2 of the last 2 reported quarters, going back to Q4 2025.

Latest position (Q1 2026)3.67M sh
Reported value held$2.69M
Portfolio Weight5.11%
First reportedQ4 2025
Last changeReduce
Updated2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

How SymBiosis Capital Partners, LLC's RANI position evolved

SymBiosis Capital Partners, LLC first disclosed a stake in RANI in Q4 2025 at 6,300,000 shares (US$8.5M). Across 2 filings, SymBiosis Capital Partners, LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q1 2026) shows 3,667,585 shares valued at US$2.7M — a reduction of -2,632,415 shares quarter over quarter.. Notable position changes include a 42% trim in Q1 2026 (shares rose 3% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 6.30M $8.51M New
Q1 2026 3.67M $2.69M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RANI and 13F data

RANI (Rani Therapeutics Holdings Inc Class A) is a Health Care company. 30 other funds we track also report a position in RANI — the largest reported positions include Samsara BioCapital, LLC (US$7.9M), Nan Fung Group Holdings Ltd (US$375K), UNITED SERVICES AUTOMOBILE ASSOCIATION (US$230K). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RANI

All RANI fund holders →

FAQ

How long has SymBiosis Capital Partners, LLC held RANI?

SymBiosis Capital Partners, LLC has disclosed RANI holdings in 2 of the last 2 reported quarters, going back to Q4 2025.

What is SymBiosis Capital Partners, LLC's current position in RANI?

As of Q1 2026, SymBiosis Capital Partners, LLC holds 3.67M shares of RANI (Rani Therapeutics Holdings Inc Class A), valued at $2.69M, representing 5.11% of its reported portfolio and ranking #4.

Has SymBiosis Capital Partners, LLC been buying or selling RANI?

In the latest 13F filing (Q1 2026), SymBiosis Capital Partners, LLC reduced its position in RANI.

Which other funds hold RANI?

Other major institutional holders of RANI include Samsara BioCapital, LLC, Nan Fung Group Holdings Ltd, UNITED SERVICES AUTOMOBILE ASSOCIATION, among 30 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.